

Challenge

The trial faced significant recruitment challenges due to the difficulty of identifying and enrolling early-stage, treatment-naïve Parkinson's disease patients, a highly specific and limited patient population. Enrollment was further jeopardized by an underperforming referral vendor and slower-than-anticipated recruitment at traditional clinical sites, which placed the study's aggressive six-month enrollment timeline at risk. These factors created an urgent need for a more effective recruitment strategy to keep the trial on track.

Solution

To address these recruitment and operational challenges, Science 37 was added to the study to streamline screening and reduce participant burden. Investigators reviewed each participant's medical history, allowing screening activities to begin immediately after consent. Research nurses conducted remote modified MDS-UPDRS examinations with video capture for centralized movement disorder specialist review. Comprehensive remote clinical evaluations included MDS-UPDRS Parts I-III, PDQ-39, CGI assessments, safety monitoring, and biomarker collection, supporting high-quality data collection while allowing participants to complete study activities from home.

Science 37 Results

Science 37 exceeded its enrollment commitment, became the study's highest enrolling site, and maintained exceptional participant retention despite challenging eligibility criteria.

77%

**of Total Study
Participant Enrolled**

Science 37: 46 patients
4 Traditional Sites
Combined: 14 patients

115%

**of Original
Enrollment Target**

Exceeded the
initial contract
of 40 patients

98%

**of Original
Enrollment Retained**

45 of 46 patients
completed
the study



Watch Participant Testimonial Video



Scan to Learn More about Our Direct-to-Patient Site.

© 2026 Science 37. All rights reserved. This material is confidential and proprietary to Science 37 and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

www.science37.com



**The First & Only FDA-Inspected
Direct-to-Patient Site**